Pluripotency of Induced Pluripotent Stem Cells

Chunjing Feng1,2,3, Yun-Dan Jia1,2, Xiao-Yang Zhao1,2,*

1 State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
2 Key Laboratory of Translational Stem Cell Research, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
3 University of Chinese Academy of Sciences, Beijing 100049, China

Received 2 August 2013; accepted 17 August 2013
Available online 5 October 2013

Abstract Induced pluripotent stem (iPS) cells can be generated by forced expression of four pluripotency factors in somatic cells. This has received much attention in recent years since it may offer us a promising donor cell source for cell transplantation therapy. There has been great progress in iPS cell research in the past few years. However, several issues need to be further addressed in the near future before the clinical application of iPS cells, like the immunogenicity of iPS cells, the variability of differentiation potential and most importantly tumor formation of the iPS derivative cells. Here, we review recent progress in research into the pluripotency of iPS cells.

Introduction

Induced pluripotent stem (iPS) cells can be derived from mouse somatic cells via the ectopic expression of four defined factors, Oct4, Sox2, Klf4 and c-Myc (also known as Yamanaka factors) [1]. The mouse iPS cells express pluripotency markers and both X chromosomes are reactivated, allowing differentiation into various cell types of three germ layers when injected into a blastocyst. iPS technology makes reprogramming much easier [2,3] in comparison to early reprogramming methods such as somatic cell nuclear transfer (SCNT) [4,5]. iPS technology also circumvents the ethical problems arising from the use of human oocytes. In addition, the generation of patient-specific iPS cells could be used to screen new drugs [6,7]. However, there are currently several limitations in applying iPS cells clinically. Efficiency of converting somatic cells to iPS cells is still very low. In particular, only approximately 0.1% to 1% of somatic cells experience changes at the transcriptional level and finally become pluripotent stem cells when non-integration approaches are used [8]. Moreover, compared to embryonic stem (ES) cells, the developmental potential and differentiation capacity of iPS cells is significantly reduced and there is increased variability among all iPS cell lines [9]. In mice, only small proportions of these cells are fully reprogrammed based on the most stringent tetraploid complementation assay for evaluating pluripotency [10–13]. Therefore, it is necessary to establish a strict molecular standard system to distinguish fully reprogrammed iPS cells from those partially reprogrammed, as we currently lack suitable in vivo pluripotency tests for human iPS cells.

In this review, we mainly focus on recent progress on rodent, non-human primate and human iPS cells, and point out some key questions which need to be addressed in the near future, such as the pluripotency level of human iPS cells and...
the establishment of a new standard to assess the pluripotency level of human iPS cells.

**Generation of non-integration iPS cells**

Takahashi and Yamanaka reprogrammed mouse embryonic fibroblasts by the ectopic expression of four reprogramming factors using retroviral vectors, and finally produced iPS cells which resemble ES cells [1]. This original iPS reprogramming approach used viral vectors, including retrovirus and lentivirus which possess high reprogramming efficiency [14,15]. The genome may be mutated by integrating other gene sequences, thus raising concerns on the safety issue. In addition, the insertion of oncogenes, like c-Myc, increases the risk of tumor formation [16,17]. Subsequently, several modified methods were used to obtain much safer iPS cells, for instance, piggyBac transposon [18], adenovirus [19], sendai virus [20], plasmid [21], episomal vectors [22] and minicircle vectors [23]. However, the reprogramming efficiency is significantly decreased and it takes longer to reactivates the key pluripotency markers to achieve full reprogramming. Therefore, efficient generation of non-integrated iPS cells by new approaches may promote their clinical application.

Recent studies have described several reprogramming methods using proteins, RNAs and small-molecule compounds to derive safe iPS cells [24–26]. Zhou et al. obtained iPS cells induced by recombination of the proteins of the four Yamanaka factors obtained by fusing the C-terminus of the proteins with poly-arginine (11R) [24]. A recent study reported that mouse and human iPS cells can be efficiently generated by miRNA mediated reprogramming [25]. Miyoshi et al. [26] successfully generated iPS cells by direct transfection of human somatic cells using mature miRNA. iPS cells can also be generated by synthetic RNAs, which bypass the innate response to viruses [27]. Recently, Houet et al. [28] showed that pluripotent stem cells can be generated from mouse somatic cells at an efficiency of 0.2% by using a combination of seven small-molecule compounds. Compared to traditional viral methods, the aforementioned approaches can be used to generate qualified iPS cells (Table 1) without the risk of insertional mutagenesis. Nonetheless, some familiar drawbacks exist, such as a longer and less efficient reprogramming process. In other words, what we need to do next is to optimize non-integration induction systems in order to resolve these drawbacks.

**The pluripotency of mouse iPS cells**

Pluripotency of mouse ES and iPS cells can be detected by a series of testing standards. These standards include the expression of pluripotency markers, alkaline phosphatase (AP) staining, teratoma formation in vitro, the formation of diploid chimera, and tetraploid complementation. The first-generation of iPS cells resemble ES cells in morphology and express some pluripotency markers, but are not able to produce live chimeric mice [1], indicating that the original iPS cells were not fully reprogrammed to pluripotent stem cells. Subsequently, modified protocols were used for reprogramming to create improved qualified iPS cells, which resulted in the generation of live chimeric mice with germline transmission [16,29].

Whether fully reprogrammed pluripotent stem cells have the ability to generate iPS-mice through tetraploid complementation has been questioned for a long time until 2009, when live pups were finally generated in two independent research laboratories [12,13]. Since then, no matter reprogrammed by one or three factors [30,31], using adult or fetal cells [13,32], the iPS cells are able to generate iPS-mice, even after genetic modification.

However, not all mouse iPS cells are able to pass the most rigorous tetraploid complementation assessment. Therefore it is important to identify molecular markers which can predict the pluripotency level of iPS cells, which will help future mechanistic studies. A small number of transcriptionally active genes within the imprinted Dlk1-Dio3 gene cluster on chromosome 12qF1, particularly Glt2 and Rian, are aberrantly

| Table 1 | Summary of different reprogramming methods for the generation of iPS cells |
|---------|--------------------------------------------------------------------------------|
| **Viral or nonviral** | **Type of vector** | **Genomic integration** | **Advantages** | **Disadvantages** | **Ref** |
| Viral | Retrovirus | Yes | Stably integrated into the host genome; high efficiency | Too risky because of their insertional tendencies; cause tumor formation | [1,16] |
| | Lentivirus | Yes | Reduces the risk of transgene expression; high efficiency | Too risky because of their insertional tendencies | [14] |
| | Adenovirus | No* | Lacking viral integration; high efficiency | Tend to carry the virus genome | [19] |
| | Sendai virus | No** | Lacking viral integration; high efficiency | Tend to carry the virus genome | [20] |
| Nonviral | piggyBac transposon | No*** | Virus-free | A labor-intensive process | [18] |
| | Plasmid | No* | Virus-free; no integration of the plasmid into the host genome | Lower efficiency; four rounds of transfection | [21] |
| | Episomal vector | No* | Virus-free; a single transfection | Lower efficiency | [22] |
| | Minicircle vector | No* | Virus-free; higher transfection efficiency | Longer ectopic expression | [23] |
| | Protein | No | Virus-free | Lower efficiency | [24] |
| | RNA | No | Virus-free; high efficiency | Labor-intensive procedures | [25–27] |
| | Small molecule | No | Virus-free | Lower efficiency | [28] |

* Lack of genomic integration can be examined; ** lack of virus RNA genome can be examined; *** transposon vector can be removed from the genome.
silenced in most iPS cell lines. These iPS cell lines poorly contribute to chimeras and fail to support the development of iPS cell-derived embryos generated by tetraploid complementation [33,34]. In contrast, in fully pluripotent iPS cell lines these genes are expressed at levels comparable to those in embryonic stem cells.

The pluripotency of human iPS cells

Human iPS cells produced via somatic cell reprogramming have opened up another new territory for regenerative medicine. Human iPS cells generated from adult human fibroblasts express hES cell-specific surface antigens, including SSEA-3, SSEA-4, tumor-related antigen (TRA)-1–60, TRA-1–81 and NANOG protein, while displaying high telomerase activity and multiple differentiation potential [35–37]. In addition, human iPS cells can differentiate into cells of all three germ layers. However, unlike the mouse situation, there are no suitable in vivo testing standards for human ES/iPS cells available that can be applied to test the in vivo functions in embryonic development and pluripotency. As a result, the failure to distinguish pluripotent cell lines will hinder clinical application in the future (Table 2).

The pluripotency of naïve iPS cells

Pluripotency can be defined as the ability of a single cell to differentiate into all types of somatic cells in an adult organism. Rodent pluripotent stem cells can be considered to exist in two distinct states: naïve and primed [38]. Rodent naïve pluripotent stem cells can be derived through expansion of the inner cell mass (ICM) of the blastocyst, the reprogramming of somatic cells, or the reversion of primed pluripotent cells. Rodent primed pluripotent stem cells can be accessed through harvesting the post-implantation epiblast or pre-implantation blastocyst [39–41]. Naïve and primed iPS cells have some common characteristics: indefinite self-renewal, tri-germ layer differentiation potential and reliance on the core transcription factors Oct4, Sox2 and Nanog. However, naïve pluripotent stem cells are distinguished from primed cells in that they rely mainly on leukemia inhibitory factor (LIF) signaling and MEK/GSK3 inhibition to maintain their self-renewal, two active X chromosomes in female cells and pluripotency to generate high-grade chimeras, even tetraploid complementation animal [11,42–44]. Primed pluripotent stem cells, however, depend on the Activin-nodal signaling pathway. They generate chimeric mice with low efficiency and fail to contribute to the germline of chimeric mice [40].

Human embryonic stem cells are derived from pre-implantation blastocysts and more closely resemble mouse epiblast stem cells in pluripotency level, when compared with rodent counterparts [45]. In fact, several attempts to capture human naïve pluripotent stem cells have been carried out. Naïve-like female human ES cells (with two active X chromosomes) were derived in 5% oxygen and conventional human ES culture conditions containing bFGF [46]. NANOG-positive cells can be harvested from human pre-implantation embryos and maintained in vitro at physiological oxygen concentrations when supplemented with FGF inhibitor or 2i, which is used to stabilize naïve rat ES cells. This suggests that some transient naïve cells may exist in early human embryos [47,48]. Though we have witnessed exciting progress in the field of naïve human pluripotent stem cells research, definitive evidence for naïve

### Table 2 Pluripotency levels of ES/iPS cells vary among different species

| Cell type | Species          | Pluripotency markers | AP staining | Teratoma formation | Diploid chimera/germline | Tetraploid complementation | Ref                          |
|-----------|------------------|----------------------|-------------|--------------------|--------------------------|---------------------------|------------------------------|
| ES/iPS    | Mouse            | Positive             | Positive    | Yes                | Yes/Yes                  | Yes                       | [1,16]                       |
| ES/iPS    | Rat              | Positive             | Positive    | Yes                | Yes/Yes                  | Unknown                   | [47]                         |
| ES/iPS    | Human            | Positive             | Positive    | Yes                | \                         | \                         | [35,45]                     |
| ES/iPS    | Rhesus monkey    | Positive             | Positive    | Yes                | Unknown/Unknown          | Unknown                   | [49–51]                     |

Note: \ indicates that chimera assay cannot be used in human ES/iPS pluripotency test.

![Figure 1 Comparison of pluripotency levels of iPS cells from mouse, human and monkey](image-url)
human pluripotent stem cell state is lacking. Although reprogramming mouse embryonic fibroblast using the four Yama-
naka factors in mouse ES culture medium yields naïve mouse iPSCs, similar endeavor in reprogramming human embryonic fibroblasts by applying naïve culture condition generates human iPSC cell lines that lack characteristic qualities seen in bona fide mouse ES/iPS cells \[1,15\]. This suggests a critical question: whether human naïve-specific pluripotent stem cells can feature characteristics seen in rodent cell lines.

Non-human primate ES cells and iPSCs share very similar characteristics with regard to pluripotency markers, gene expression and ability to differentiate into all three germ layers \[49,50\]. The chimera assay can be used to distinguish primed and naïve rodent pluripotent stem cells, which cannot be used on human cells. Non-human primate cells may be the most ideal substitute to test the rodent paradigm (Figure 1). Similar to mouse primed stem cells (epiblast stem cells), a report shows that rhesus monkey ES cells cannot produce high-grade chimeric embryos or blastocysts \[51\], although ES cells can be observed in the ICM of blastocyst transiently when introduced to four-cell stage embryos. These results suggest that non-human primate embryonic stem cells are therefore primed stem cells. Primates, as the model animal most similar to human, can be used for chimera arrays to screen Naïve pluripotent stem cells. Additionally, development of new methods to functionally evaluate non-human pluripotent stem cells, such as by establishing a fetal chimera array, may help to evaluate the pluripotency level of human pluripotent stem cells in the future.

Competing interests

The authors declared that no competing interests exist.

Acknowledgements

This work was supported by grants from the National Basic Research Program of China (Grant No. 2012CBA01300 and 2012CB966500).

References

[1] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–76.
[2] Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996;380:64–6.
[3] Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997;385:810–3.
[4] Wakayama T, Tabar V, Rodriguez I, Perry AC, Studer L, Mombaerts P. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science 2001;292:740–3.
[5] Tachibana M, Amato P, Sparman M, Gutierrez NM, Tippner-Hedges R, Ma H, et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013;153:1228–38.
[6] Park IH, Arora N, Hsiao H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877–86.
[7] Mou X, Wu Y, Cao H, Meng Q, Wang Q, Sun C, et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res Ther 2012;3:14.
[8] Liang G, Taranova O, Xia K, Zhang Y. Butyrate promotes induced pluripotent stem cell generation. J Biol Chem 2010;285:25516–21.
[9] Hu BY, Weick JP, Yu J, Ma LX, Zhang XQ, Thomson JA, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 2010;107:4335–40.
[10] Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culture-derived mice from early-
passage embryonic stem cells. Proc Natl Acad Sci U S A 1993;90:8424–8.
[11] Nagy A, Gocz E, Diaz EM, Prideaux VR, Ivanyi E, Markkula M, et al. Embryonic stem cells alone are able to support fetal development in the mouse. Development 1990;110:815–21.
[12] Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. Adult mice generated from induced pluripotent stem cells. Nature 2009;461:91–4.
[13] Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of disease-specific induced pluripotent stem cells from mouse embryonic fibroblasts by applying naïve culture conditions generated from cell lines. Stem Cells 2009;27:543–9.
[14] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–72.
[15] Okita K, Ichisaka T, Yamanaka S. Generation of germline-
competent induced pluripotent stem cells. Nature 2007;448:313–7.
[16] Tong M, Lv Z, Liu L, Zhu H, Zheng QY, Zhao XY, et al. Mice generated from tetraploid complementation competent iPSC cells show similar developmental features as those from ES cells but are prone to tumorigenesis. Cell Res 2011;21:1634–7.
[17] Woltjen K, Michael JP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, et al. PiggyBac transposition reprograms fibro-
basts to induced pluripotent stem cells. Nature 2009;458:766–70.
[18] Stadtfeld M, Nagaya M, Utitkal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945–9.
[19] Fusaki N, Ban H, Nishiyaama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:348–62.
[20] Otaka K, Hon H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010;5:418–26.
[21] Yu J, Hu K, Smaga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797–801.
[22] Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, et al. A nonviral minicircle vector for deriving human iPSC cells. Nat Methods 2010;7:197–9.
[23] Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381–4.
[24] Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011;8:633–8.
[25] Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed
differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618–30.

[28] Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013;341:651–4.

[29] Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318–24.

[30] Kang L, Wu T, Tao Y, Yuan Y, He J, Zhang Y, et al. Viable mice produced from three-factor induced pluripotent stem (iPS) cells through tetraploid complementation. Cell Res 2011;21:546–9.

[31] Yuan X, Wan H, Zhao X, Zhu S, Zhou Q, Ding S. Combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. Stem Cells 2011;29:549–53.

[32] Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. Viable fertile mice generated from fully pluripotent iPS cells derived from adult somatic cells. Stem Cell Rev 2010;6:390–7.

[33] Liu L, Luo GZ, Yang W, Zhao X, Zheng Q, Lv Z, et al. Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells. J Biol Chem 2010;285:19483–90.

[34] Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010;465:175–81.

[35] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917–20.

[36] Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402–6.

[37] Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013;494:105–10.

[38] Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell 2009;4:487–92.

[39] Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, et al. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007;448:196–9.